When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
SNGX - Soligenix completes patient enrollment late-stage CTCL study
Soligenix Inc.
Soligenix (NASDAQ:SNGX) has completed patient enrollment in its Phase 3 "Fluorescent Light Activated Synthetic Hypericin" (FLASH) study for SGX301 (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL).
More news on: Soligenix, Inc., Healthcare stocks news,